Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when? (Q34788219)

4 August 2017

1 reference

title

Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when? (English)

1 reference

4 August 2017

Jones MP

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Postgraduate Medical Journal

4 August 2017

published in

1 reference

4 August 2017

volume

78

1 reference

4 August 2017

issue

922

1 reference

4 August 2017

page(s)

465-468

1 reference

Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Costs of Acid-Related Disorders to a Health Maintenance Organization

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Review article: drug therapy for reflux oesophagitis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

26 October 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

26 October 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1742452

An evidence-based appraisal of reflux disease management--the Genval Workshop Report

9 December 2018

1 reference

12 December 2020

Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures

1 reference

12 December 2020

Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases

1 reference

12 December 2020

Empiric Therapy for Gastroesophageal Reflux Disease

1 reference

12 December 2020

The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms

1 reference

12 December 2020

Identifiers

DOI

10.1136/PMJ.78.922.465

1 reference

4 August 2017

1 reference

4 August 2017

1 reference